The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, medicare, and medicaid
Head and neck cancers are of particular interest to health care providers, their patients, and those paying for health care services, because they have a high morbidity, they are extremely expensive to treat, and of the survivors only 48% return to work. Consequently the economic burden of oral cavity, oral pharyngeal, and salivary gland cancer (OC/OP/SG) must be understood. The cost of these cancers in the U.S. has not been investigated.
A retrospective analysis of administrative claims data for 6,812 OC/OP/SG cancer patients was undertaken. Total annual health care spending for OC/OP/SG cancer patients was compared to similar patients without OC/OP/SG cancer using propensity score matching for enrollees in commercial insurance, Medicare, and Medicaid. Indirect costs, as measured by short term disability days were compared for employed patients.
Total annual health care spending for OC/OP/SG patients during the year after the index diagnosis was $79,151 for the Commercial population. Health care costs were higher for OC/OP/SG cancer patients with Commercial Insurance ($71,732, n = 3,918), Medicare ($35,890, n = 2,303) and Medicaid ($44,541, n = 585) than the comparison group (all p < 0.01). Commercially-insured employees with cancer (n = 281) had 44.9 more short-term disability days than comparison employees (p < 0.01). Multimodality treatment was twice the cost of single modality therapy. Those patients receiving all three treatments (surgery, radiation, and chemotherapy) had the highest costs of cost of care, from $96,520 in the Medicare population to $153,892 in the Commercial population.
In the U.S., the cost of OC/OP/SG cancer is significant and may be the most costly cancer to treat in the U.S. The results of this analysis provide useful information to health care providers and decision makers in understanding the economic burden of head and neck cancer. Additionally, this cost information will greatly assist in determining the cost-effectiveness of new technologies and early detection systems. Earlier identification of cancers by patients and providers may potentially decrease health care costs, morbidity and mortality.
- Centers for Medicare and Medicaid Services, National Health Statistics Group, National Health Care Expenditures Data January 2010.
- Kaiser Family Foundation and Health Research and Educational Trust: Employer Health Benefits2009 Annual Survey. September 2009.
- Funk GF, Hoffman HT, Hynds Karnell L, Ricks JM, Zimmerman B, Corbae DP, Hussey DH, McCulloch TM, Graham SM, Dawson CJ, Means ME, Colwill ML, Titler MG, Smith EM: Cost-identification analysis in oral cavity cancer management. Otolaryngol Head Neck Surg 1998, 118:211–220. CrossRef
- Epstein JD, Knight TK, Epstein JB, Bride MA, Nichol MB: Cost of care for early- and late-stage oral and pharyngeal cancer in the California Medicaid population. Head Neck 2008 Feb,30(2):178–186. CrossRef
- Lang K, Sussman M, Friedman M, Su J, Kan HJ, Mauro D, Tafesse E, Menzin J: Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2009,135(6):582–588. CrossRef
- Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA: Cancer treatment cost in the United States: has the burden shifted over time? Cancer 2010,116(14):3477–3484. CrossRef
- Taylor JC, Terrell JE, Ronis DL, Fowler KE, Bishop C, Lambert MT, Myers LL, Duffy SA, Bradford CR, Chepeha DB, Hogikyan ND, Prince ME, Teknos TN, Wolf GT: Disability in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2004,130(6):764–769. CrossRef
- Ramsey SD, Fedorenko CR, Snell KS, Kirchhoff AC, Hollingworth W, Blough DK: Cancer diagnosis as a risk factor for personal bankruptcy. J Clin Oncol 2011., 29:
- Patton L, Epstein J, Kerr R: Adjunctive techniques for oral cancer examination and lesion diagnosis. A systemic review of the literature. JADA 2008,139(7):896–905.
- Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Sternhagen A, Fraumeni JF: Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988, 48:3282–3287.
- Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709–720. CrossRef
- Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, Fernández L, Idris A, Sánchez MJ, Nieto A, Talamini R, Tavani A, Bosch FX, Reidel U, Snijders PJ, Meijer CJ, Viscidi R, Muñoz N, Franceschi S: Human papillomavirus and oral cancer: the International Agency for Research on Cancer Multicenter Study. J Natl Cancer Inst 2003, 95:1772–1783. CrossRef
- Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (Eds): SEER Cancer Statistics Review. National Cancer Institute, Bethesda, MD; 1975–2007. http://seer.cancer.gov/csr/1975_2007/ based on November 2009 SEER data submission, posted to the SEER web site, 2010
- Schantz SP, Yu G-P: Head and neck cancer incidence trends in young Americans, 1973–1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg 2002, 128:268–274.
- Kademani D: Oral cancer. Mayo Clin Proc 2007,82(7):878–887. CrossRef
- National Cancer Institute: What you need to know about oral cancer: Treatment. [ http://www.cancer.gov/cancertopics/wyntk/oral/page8]
- Katz MR, Irish JC, Devins GM, Rodin GM, Gullane PJ: Psychosocial adjustment in head and neck cancer: the impact of disfigurement, gender and social support. Head Neck 2003,25(2):103–112. CrossRef
- National Institute of Dental and Craniofacial Research, National Institutes of Health [http://www.nidcr.nih.gov/DataStatistics/FindDataByTopic/OralCancer/]
- American Cancer Society [http://www.cancer.org/Cancer/OralCavityandOropharyngealCancer]
- Parsons LS: Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In Proceedings of the Twenty-sixth Annual SAS® Users Group International Conference. Cary: SAS Institute Inc; 2001:214–226.
- D'Hoore W, Bouckaert A, Tilquin C: Practical considerations on the use of the Charlson Comorbidity Index with administrative data bases. J Clin Epidemiol 1996, 49:1429–1433. CrossRef
- Ashcraft ML, Fries BE, Nerenz DR, Falcon SP, Srivastava SV, Lee CZ, Berki SE, Errera P: A psychiatric patient classification system: an alternative to diagnosis-related groups. Medical Care 1989, 27:543–557. CrossRef
- Bureau of Labor Statistics: Consumer Price Index Inflation Calculator. [ http://stats.bls.gov/data/inflation_calculator.htm]
- Employer costs for employee compensation – December 2009 (2010). Bureau of Labor Statistics, U.S. Department of Labor; USDL-10–0283. [ http://www.bls.gov/news.release/archives/ecec_03102010.pdf] USDL-10-0283.
- Kitamura M, Hirano S, Tateya I, Kada S, Ishikawa S, Kanda T, Asata R, Ito J: Ten years single institutional experience of treatment for oral cancer in Kyoto University. Acta Otolaryngol Suppl 2010, 563:74–78. CrossRef
- Lawless GD: The working patient with cancer: implications for payers and employers. American Health and Drug Benefits 2009,2(4):168–173.
- Short P, Moran J, Rajeshwari P: Medical expenditures of adult cancer survivors aged <65 years in the United States. Cancer 2011,117(12):2791–2800. CrossRef
- Hollenbeak CS, Stack BC, Daley SM, Piccirillo JF: Using comorbidity indexes to predict costs for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007, 133:24–27. CrossRef
- Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML: Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008, 100:630–641. CrossRef
- Elting LS, Cooksley CD, Chambers MS, Garden AS: Risk, outcomes and costs of radiation- induced oral mucositis among patients with head-and-neck malignancies. Int J Radiational Oncology Biol Phys 2007,68(4):1110–1120. CrossRef
- The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, medicare, and medicaid
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Head & Neck Oncology
- Online Date
- April 2012
- Online ISSN
- BioMed Central
- Additional Links
- Oral cancer
- Cost of illness
- Burden of illness
- Author Affiliations
- 1. Delta Dental of Michigan, University of Michigan, 4100 Okemos Road, Okemos, MI, 48864, USA
- 2. University of Illinois at Chicago, 1500 East Duarte Road, Duarte, CA, 91019-3000, USA
- 3. Delta Dental of Wisconsin, 2801 Hoover Road, Stevens Point, WI, 54481, USA
- 4. Thomson Reuters, 777 East Eisenhower Parkway, Ann Arbor, MI, 48108, USA
- 5. Department of Epidemiology, Thomson Reuters, RPHB, 1530 3rd Avenue South, Birmingham, AL, 35294-0022, USA
- 6. Formerly of Thomson Reuters, 15 Crescent Road, Lexington, MA, 02421, USA
- 7. Vanderbilt University, 2220 Pierce Avenue, 777 PRB, Nashville, TN, 37232-6307, USA